Table 1.
Patient Demographics
| N (%) | |
|---|---|
| Demographic Characteristic | (N=35) |
| Age, mean years (SD) | 42.5 (±13.8) |
| Male | 22 (63%) |
| Caucasian | 31 (89%) |
| Underlying malignancy | |
| AML | 17 (49%) |
| MDS | 4 (11%) |
| CML | 4 (11%) |
| Non-Hodgkin’s Lymphoma | 3 (9%) |
| ALL | 2 (6%) |
| Othera | 5 (14%) |
| CMV serologies (donor / recipient) | |
| Positive or negative / positive | 29 (83%) |
| Positive / negative | 2 (6%) |
| Negative / negative | 4 (11%) |
| Allogeneic HSCT | 35 (100%) |
| Unrelated donor | 21 (60%) |
| HLA Matched | 24 (69%) |
| Peripheral Blood HSCT | 19 (54%) |
| Conditioning regimen | |
| Cyclophosphamide / Single-dose TBI (550cGy) | 23 (65%) |
| Busulfan / Cyclophosphamide | 6 (17%) |
| Fractionated TBI / Cyclophosphamide | 3 (9%) |
| Other | 3 (9%) |
| Graft versus host disease | 25 (71%) |
| Skin | 23 (66%) |
| Gastrointestinal | 11 (31%) |
| Hepatic | 5 (14%) |
| Steroid use, mean days (SD) | 39 (±20) |
| Charlson Comorbidity Index at HSCT, median (range)b | 2.5 (2–5) |
SD – Standard deviation; AML – Acute Myelogenous Leukemia; MDS – Myelodysplastic Syndrome; CML – Chronic Myelogenous Leukemia; ALL – Acute Lymphoblastic Leukemia; CMV – Cytomegalovirus; HSCT – Hematopoietic Stem Cell Transplant; HLA – Human Leukocyte Antigen; TBI – Total Body Irradiation
a
Other malignancies included aplastic anemia, prolymphocytic leukemia, and Hodgkin’s lymphoma
b
Age was not scored, as it was evaluated as a separate factor